Prakash P Punjabi

Prof. Prakash P Punjabi

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
JCJohn C Chambers
John C Chambers
MLMarie Loh
Marie Loh
BLBenjamin Lehne
Benjamin Lehne
ADAlexander Drong
Alexander Drong
JKJennifer Kriebel
Jennifer Kriebel
JKJaspal S Kooner
Jaspal S Kooner

10 March 2019 in Aging Cell
Verified
Journal Article
Open access
PDF file
FLFiona C. Lewis‐McDougall
Fiona C. Lewis‐McDougall
PRPrashant J. Ruchaya
Prashant J. Ruchaya
EDEva Domenjo‐Vila
Eva Domenjo‐Vila
TTTze Shin Teoh
Tze Shin Teoh
LPLarissa Prata
Larissa Prata
GEGeorgina M Ellison-Hughes
Georgina M Ellison-Hughes
Aging leads to increased cellular senescence and is associated with decreased potency of tissue‐specific stem/progenitor cells. Here, we have done an extensive analysis of cardiac progenitor cells (CPCs) isolated from human subjects with cardiovascular disease, aged 32–86 years. In aged subjects (>70 years old), over half of CPCs are senescent (p16INK4A, SA‐β‐gal, DNA damage γH2AX, telomere length, senescence‐associated secretory phenotype [SASP]), unable to replicate, differentiate, regenerate or restore cardiac function following transplantation into the infarcted heart. SASP factors secreted by senescent CPCs renders otherwise healthy CPCs to senescence. Elimination of senescent CPCs using senolytics abrogates the SASP and its debilitative effect in vitro. Global elimination of senescent cells in aged mice (INK‐ATTAC or wild‐type mice treated with D + Q senolytics) in vivo activates resident CPCs and increased the number of small Ki67‐, EdU‐positive cardiomyocytes. Therapeutic approaches that eliminate senescent cells may alleviate cardiac deterioration with aging and restore the regenerative capacity of the heart.

20 November 2012 in Circulation
Verified
Journal Article
Closed access
PDF file
KCK.M. John Chan
K.M. John Chan
PPPrakash P Punjabi
Prakash P Punjabi
MFMarcus Flather
Marcus Flather
RWRiccardo Wage
Riccardo Wage
KSKaren Symmonds
Karen Symmonds
JPJohn R. Pepper
John R. Pepper
Background—: The role of mitral valve repair (MVR) during coronary artery bypass grafting (CABG) in patients with moderate ischemic mitral regurgitation (MR) is uncertain. We conducted a randomized, controlled trial to determine whether repairing the mitral valve during CABG may improve functional capacity and left ventricular reverse remodeling compared with CABG alone. Methods and Results—: Seventy-three patients referred for CABG with moderate ischemic MR and an ejection fraction >30% were randomized to receive CABG plus MVR (34 patients) or CABG only (39 patients). The study was stopped early after review of interim data. At 1 year, there was a greater improvement in the primary end point of peak oxygen consumption in the CABG plus MVR group compared with the CABG group (3.3 mL/kg/min versus 0.8 mL/kg/min; P <0.001). There was also a greater improvement in the secondary end points in the CABG plus MVR group compared with the CABG group: left ventricular end-systolic volume index, MR volume, and plasma B-type natriuretic peptide reduction of 22.2 mL/m 2 , 28.2 mL/beat, and 557.4 pg/mL, respectively versus 4.4 mL/m 2 ( P =0.002), 9.2 mL/beat ( P =0.001), and 394.7 pg/mL ( P =0.003), respectively. Operation duration, blood transfusion, intubation duration, and hospital stay duration were greater in the CABG plus MVR group. Deaths at 30 days and 1 year were similar in both groups: 3% and 9%, respectively in the CABG plus MVR group, versus 3% ( P =1.00) and 5% ( P =0.66), respectively in the CABG group. Conclusions—: Adding mitral annuloplasty to CABG in patients with moderate ischemic MR may improve functional capacity, left ventricular reverse remodeling, MR severity, and B-type natriuretic peptide levels, compared with CABG alone. The impact of these benefits on longer term clinical outcomes remains to be defined. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00413998.

1 October 2009 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SCStuart A Cook
Stuart A Cook
AVAnabel Varela-Carver
Anabel Varela-Carver
MMMarco Mongillo
Marco Mongillo
CKChristina Kleinert
Christina Kleinert
MKMuhammad T. Khan
Muhammad T. Khan
PCPaolo G. Camici
Paolo G. Camici
Whole body and myocardial insulin resistance are features of non-insulin-dependent diabetes mellitus (NIDDM) and left-ventricular dysfunction (LVD). We determined whether abnormalities of insulin receptor substrate-1 (IRS1), IRS1-associated PI3K (IRS1-PI3K), and glucose transporter 4 (GLUT4) contribute to tissue-specific insulin resistance. We collected skeletal muscle (n = 27) and myocardial biopsies (n = 24) from control patients (n = 7), patients with NIDDM (n = 9) and patients with LVD (n = 8), who were characterized by euglycaemic–hyperinsulinaemic clamp and positron emission tomography. Comparative studies were carried out in three mouse models. We demonstrate an unrecognized reduction of IRS1 in skeletal muscle of LVD patients and an unexpected increase in cardiac IRS1-PI3K activity in NIDDM and LVD patients. In NIDDM, there was a concomitant reduction in sarcolemmal GLUT4, whereas in patients with LVD sarcolemmal GLUT4 was increased. We confirm activation of IRS1-PI3K and reduction in sarcolemmal GLUT4 in the insulin resistant ob/ob mouse heart where we also demonstrate perturbation of GLUT4 docking and fusion. A direct relationship between PI3K and GLUT4 was demonstrated in mice expressing activated PI3K in the heart and increased GLUT4 at the sarcolemma was confirmed in a mouse model of LVD. Our data show that the mechanisms of myocardial insulin resistance are different between NIDDM and LVD.

26 January 2016 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
KAKyriakos Anastasiadis
Kyriakos Anastasiadis
JMJohn Murkin
John Murkin
PAPolychronis Antonitsis
Polychronis Antonitsis
ABAdrian Bauer
Adrian Bauer
Marco RanucciMarco Ranucci
Marco Ranucci
TCThierry Pierre Carrel
Thierry Pierre Carrel
Minimal invasive extracorporeal circulation (MiECC) systems have initiated important efforts within science and technology to further improve the biocompatibility of cardiopulmonary bypass components to minimize the adverse effects and improve end-organ protection. The Minimal invasive Extra-Corporeal Technologies international Society was founded to create an international forum for the exchange of ideas on clinical application and research of minimal invasive extracorporeal circulation technology. The present work is a consensus document developed to standardize the terminology and the definition of minimal invasive extracorporeal circulation technology as well as to provide recommendations for the clinical practice. The goal of this manuscript is to promote the use of MiECC systems into clinical practice as a multidisciplinary strategy involving cardiac surgeons, anaesthesiologists and perfusionists.

28 April 2008 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
EPEnrico Petretto
Enrico Petretto
RSRizwan Sarwar
Rizwan Sarwar
IGIan Grieve
Ian Grieve
HLHan Lu
Han Lu
MKMande K Kumaran
Mande K Kumaran
SCStuart A Cook
Stuart A Cook